Shareholder Return Policies
Annual return to shareholders
별도 FCF의 50%
* FCF: 영업현금흐름 - CAPEX
* CAPEX: 유무형자산취득 + 지분투자(메자닌 등 포함)
Dividend to shareholders
3년간 300억원 이상 배당 예정
분기배당 정책 유지
주식배당 매년 3% 지급
Treasury Shares
주주환원 규모 내에서 배당 후 잔여재원으로 자기주식 매입 및 소각 예정
Shareholder Return Policies
Annual return to shareholders
30% of consolidated net income (less non-ordinary gains)
Dividend to shareholders
KRW 30+B annually, over 3 years to come
Interim dividend payout
Treasury Shares
By paying out dividends within the above annual return to shareholders, followed by repurchase and retirement of treasury shares
Consequence of shareholder return
in millions KRW
| Category | 2024 | 2025 | 2026 | Sum |
|---|---|---|---|---|
| Interim Dividend | - | - | - | - |
| Final Dividend | - | - | - | - |
| Dividends Total | - | - | - | - |
| Treasury Shares Repurchased & Retired | - | - | - | - |
| Amount Returned to Shareholders | - | - | - | - |
Consequence of shareholder return
in millions KRW
| Category | 2023 | 2022 | 2021 | Sum |
|---|---|---|---|---|
| Interim Dividend | 6,251 | 3,125 | 3,125 | 12,501 |
| Final Dividend | 7,501 | 6,251 | 6,250 | 20,002 |
| Dividends Total | 13,752 | 9,376 | 9,375 | 35,503 |
| Treasury Shares Repurchased & Retired | - | - | - | - |
| Amount Returned to Shareholders | 13,752 | 9,376 | 9,375 | 32,503 |
5-year Dividend Payout
| Category | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Face Value(KRW) per Share | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | |
| Dividend(KRW) per Share | Interim | 1,000 | 500 | 500 | - | - |
| Final | 1,200 | 1,000 | 1,000 | 1,000 | 1,000 | |
| Dividends Total(in millions KRW) | 13,752 | 9,376 | 9,375 | 6,057 | 6,138 | |
| Consolidated Net Income(in millions KRW)¹ | 57,990 | 11,153 | 60,271 | 162,345 ³ | 19,764 | |
| Propensity to Dividend(%) | 23.7 | 84.1 | 15.6 | 3.7 | 31.1 | |
| Dividend Yield(%) | 2.2 | 1.5 | 1.3 | 0.8 | 0.9 | |
Note 1) Consolidating owner's shares in dominant firm
Note 2) Impairment loss recognized for ST Pharm, a subsidiary of the Group
Note 3) Reversal of impairment loss recognized for ST Pharm, a subsidiary of the Group